注射用头孢拉宗体外、体内抗菌研究  

In vitro and in vivo antibacterial activity of cefbuperazone sodium

作　　者：方鉴[1] 何晓锋[2] 吴镝[2] 张虎[2] 汪娟[1] 马文杰[2] 

机构地区：[1]北京藏医院,北京100029 [2]空军总医院感染控制科,北京100142

出　　处：《空军医学杂志》2012年第3期141-145,共5页Medical Journal of Air Force

摘　　要：目的评价注射用头孢拉宗体内外抗菌活性。方法琼脂2倍稀释法测定该药对临床分离菌最低抑菌浓度(MIC)值及对细菌感染小鼠的体内保护作用,同时与对照药头孢西丁、头孢呋辛、头孢唑林进行对比。结果头孢拉宗对革兰氏阴性菌的抗菌作用较强,优于头孢西丁、头孢呋辛、头孢唑林。头孢拉宗对大肠埃希菌和金黄色葡萄球菌显示杀菌作用,酸性环境下,头孢拉宗的抗菌活性有所降低,随着细菌接种量和血清浓度的增加,头孢拉宗的抗菌活性略微降低;头孢拉宗对大肠埃希菌感染小鼠有较强的保护作用,ED50值为7.3 mg/kg,优于头孢西丁,对金黄色葡萄球菌感染小鼠ED50值为15.7 mg/kg,稍弱于头孢西丁。结论注射用头孢拉宗对临床常见的革兰氏阴性菌有较好的抗菌作用。Objective The aim was to evaluate in vitro and in vivo antibacterial activities of cefbuperazone against clinical isolates, compared with cefoxitin, cefuroxime and cefazolin. Method Minimal inhibitory concentration（MIC） tests were carried out with double agar dilution method. The affecting factors and in vivo antibacterial action were also determined. Result Cefbuperazone was more active than cefoxitin, cefuroxime and cefazolin against gram-nagative bacteria. Antibacterial activities of cefbuperazone slightly decreased under acidic, with the increase of serum concentration and of bacteria inoculum size. The protective effects of cefbuperazone against experimental systemic infections were observed. ED50 of cefbuperazone against escherichia coli and ED50 of cefbuperazone against staphylococcus were 7.3 and 15.77mg/kg respectively. Conclusion Cefbuperazone showed a good activity against gram-nagative bacteria.

关 键 词：头孢拉宗 抗菌药 

分 类 号：R978.11[医药卫生—药品]